Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
India
/
Pharmaceuticals & Biotech
/
Indoco Remedies
INDOCO
Indoco Remedies
Global Aging Trends Will Unlock Premium Generics
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 4 Analysts
Published
09 Jul 25
Updated
08 Aug 25
0
Set Fair Value
0
votes
Share
AnalystHighTarget
's Fair Value
₹325.00
9.6% undervalued
intrinsic discount
08 Aug
₹293.70
Loading
1Y
-11.0%
7D
0.7%
Author's Valuation
₹325.0
9.6% undervalued
intrinsic discount
AnalystHighTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystHighTarget Fair Value
₹325.0
9.6% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-1b
26b
2015
2017
2019
2021
2023
2025
2027
2028
Revenue ₹26.1b
Earnings ₹4.4b
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
14.26%
Pharma revenue growth rate
1.04%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
12.73%
Calculation
₹4.43b
Earnings '28
x
7.77x
PE Ratio '28
=
₹34.45b
Market Cap '28
₹34.45b
Market Cap '28
/
73.07m
No. shares '28
=
₹471.52
Share Price '28
₹471.52
Share Price '28
Discounted to 2025 @ 12.73% p.a.
=
₹329.16
Fair Value '25